IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections

IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections

Background: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory response in infectious diseases may impair a desired host response and pre-dispose to secondary infections.Methods: We retrosp...

Full description

Bibliographic Details
Main Authors: Lucas M. Kimmig, David Wu, Matthew Gold, Natasha N. Pettit, David Pitrak, Jeffrey Mueller, Aliya N. Husain, Ece A. Mutlu, Gökhan M. Mutlu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Medicine
Subjects:
COVID-19
SARS-CoV-2
tocilizumab
cytokine release syndrome
immunosuppression
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2020.583897/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2020.583897/full

Similar Items